HomeCompareSLRX vs YUM

SLRX vs YUM: Dividend Comparison 2026

SLRX yields 238.10% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRX wins by $339.49M in total portfolio value
10 years
SLRX
SLRX
● Live price
238.10%
Share price
$0.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$339.60M
Annual income
$185,958,933.65
Full SLRX calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — SLRX vs YUM

📍 SLRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRXYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRX + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRX pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRX
Annual income on $10K today (after 15% tax)
$20,238.10/yr
After 10yr DRIP, annual income (after tax)
$158,065,093.60/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, SLRX beats the other by $158,030,716.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRX + YUM for your $10,000?

SLRX: 50%YUM: 50%
100% YUM50/50100% SLRX
Portfolio after 10yr
$169.85M
Annual income
$92,999,688.58/yr
Blended yield
54.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

SLRX
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-14.5
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRX buys
0
YUM buys
0
No recent congressional trades found for SLRX or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRXYUM
Forward yield238.10%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$339.60M$107.9K
Annual income after 10y$185,958,933.65$40,443.52
Total dividends collected$322.91M$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: SLRX vs YUM ($10,000, DRIP)

YearSLRX PortfolioSLRX Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$34,510$23,809.52$10,982$282.06+$23.5KSLRX
2$113,715$76,790.22$12,189$438.29+$101.5KSLRX
3$358,160$236,484.38$13,731$688.32+$344.4KSLRX
4$1,079,339$696,107.48$15,789$1,097.12+$1.06MSLRX
5$3,115,421$1,960,529.07$18,679$1,785.08+$3.10MSLRX
6$8,622,197$5,288,696.04$22,975$2,988.18+$8.60MSLRX
7$22,905,117$13,679,366.22$29,784$5,200.49+$22.88MSLRX
8$58,470,750$33,962,275.23$41,408$9,539.16+$58.43MSLRX
9$143,588,724$81,025,021.41$63,071$18,765.27+$143.53MSLRX
10$339,598,869$185,958,933.65$107,930$40,443.52+$339.49MSLRX

SLRX vs YUM: Complete Analysis 2026

SLRXStock

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Full SLRX Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this SLRX vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRX vs SCHDSLRX vs JEPISLRX vs OSLRX vs KOSLRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.